Cargando…

A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma

INTRODUCTION: This study investigates the safety, tolerability, and preliminary efficacy of combined treatment with VEGF inhibitor bevacizumab, topoisomerase I inhibitor irinotecan, and EGFR inhibitor erlotinib in children with progressive diffuse intrinsic pontine glioma (DIPG). METHODS: Biweekly b...

Descripción completa

Detalles Bibliográficos
Autores principales:	El-Khouly, Fatma E., Veldhuijzen van Zanten, Sophie E. M., Jansen, Marc H. A., Bakker, Dewi P., Sanchez Aliaga, Esther, Hendrikse, N. Harry, Vandertop, W. Peter, van Vuurden, Dannis G., Kaspers, Gertjan J. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211596/ https://www.ncbi.nlm.nih.gov/pubmed/33963476 http://dx.doi.org/10.1007/s11060-021-03763-1

Ejemplares similares

DIPG-84. COMPLEMENTARY AND ALTERNATIVE MEDICINE IN DIFFUSE INTRINSIC PONTINE GLIOMA
por: El-Khouly, Fatma, et al.
Publicado: (2020)

Effective Drug Delivery in Diffuse Intrinsic Pontine Glioma: A Theoretical Model to Identify Potential Candidates
por: El-Khouly, Fatma E., et al.
Publicado: (2017)

A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma
por: Veldhuijzen van Zanten, Sophie E. M., et al.
Publicado: (2017)

DIPG-33. CHARACTERIZING THE NEURO-VASCULAR UNIT IN DIFFUSE INTRINSIC PONTINE GLIOMA
por: El-Khouly, Fatma E, et al.
Publicado: (2020)

State of affairs in use of steroids in diffuse intrinsic pontine glioma: an international survey and a review of the literature
por: Veldhuijzen van Zanten, Sophie E. M., et al.
Publicado: (2016)

Deceptive morphologic and epigenetic heterogeneity in diffuse intrinsic pontine glioma
por: Bugiani, Marianna, et al.
Publicado: (2017)

(18) F-FDG PET standard uptake values of the normal pons in children: establishing a reference value for diffuse intrinsic pontine glioma
por: Jansen, Marc H A, et al.
Publicado: (2014)

External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG Registry and the SIOPE DIPG Registry
por: Veldhuijzen van Zanten, Sophie E. M., et al.
Publicado: (2017)

DIPG-77. TREATMENT EXTENT AND THE EFFECT ON SURVIVAL IN DIFFUSE INTRINSIC PONTINE GLIOMA
por: Baugh, Joshua, et al.
Publicado: (2020)

In Vitro Drug Response and Efflux Transporters Associated with Drug Resistance in Pediatric High Grade Glioma and Diffuse Intrinsic Pontine Glioma
por: Veringa, Susanna J. E., et al.
Publicado: (2013)

Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?
por: El-Khouly, Fatma E., et al.
Publicado: (2019)

DDEL-05. BLOOD-BRAIN BARRIER DISRUPTION AND ENHANCED RADIOSENSITIZERS EXTRAVASATION UPON FOCUSED ULTRASOUND FOR TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA
por: Hart, Elvin ‘t, et al.
Publicado: (2020)

Overview of Current Drug Delivery Methods Across the Blood–Brain Barrier for the Treatment of Primary Brain Tumors
por: Haumann, Rianne, et al.
Publicado: (2020)

Invaders Exposed: Understanding and Targeting Tumor Cell Invasion in Diffuse Intrinsic Pontine Glioma
por: Kluiver, T. A., et al.
Publicado: (2020)

PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation
por: van Vuurden, Dannis G., et al.
Publicado: (2011)

DIPG-35. BIOLOGICAL MEDICINE FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) ERADICATION: RESULTS OF THE THREE ARM BIOMARKER-DRIVEN RANDOMIZED BIOMEDE 1.0 TRIAL
por: Grill, Jacques, et al.
Publicado: (2020)

A microRNA Prognostic Signature in Patients with Diffuse Intrinsic Pontine Gliomas through Non-Invasive Liquid Biopsy
por: Iannó, Maria F., et al.
Publicado: (2022)

Neurological Symptom Improvement After Re-Irradiation in Patients With Diffuse Intrinsic Pontine Glioma: A Retrospective Analysis of the SIOP-E-HGG/DIPG Project
por: Chavaz, Lara, et al.
Publicado: (2022)

INSP-16. Focused ultrasound-mediated blood-brain barrier disruption for the treatment of pediatric high-grade glioma
por: van Vuurden, Dannis, et al.
Publicado: (2022)

DIPG-02. USEFULNESS OF BEVACIZUMAB IN MAINTAINING QUALITY OF LIFE AT THE TIME OF DIFFUSE INTRINSIC PONTINE GLIOMA RELAPSE
por: Gomi, Akira, et al.
Publicado: (2020)

Diffuse intrinsic pontine glioma: current insights and future directions
por: Srikanthan, Dilakshan, et al.
Publicado: (2021)

Diffuse intrinsic pontine glioma: poised for progress
por: Warren, Katherine E.
Publicado: (2012)

Nanotechnology Applications for Diffuse Intrinsic Pontine Glioma
por: Bredlau, Amy Lee, et al.
Publicado: (2017)

Genomic Insights into Diffuse Intrinsic Pontine Glioma
por: Lapin, Danielle H., et al.
Publicado: (2017)

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
por: Zhang, Shu, et al.
Publicado: (2016)

Functionally-defined Therapeutic Targets in Diffuse Intrinsic Pontine Glioma: A Report of the Children’s Oncology Group DIPG Preclinical Consortium
por: Grasso, Catherine S., et al.
Publicado: (2015)

DIPG-02. Role of a Bevacizumab-based regime in the treatment of children with diffuse intrinsic pontine glioma (DIPG): a systematic review
por: Evans, Mia, et al.
Publicado: (2022)

Does a Bevacizumab-based regime have a role in the treatment of children with diffuse intrinsic pontine glioma? A systematic review
por: Evans, Mia, et al.
Publicado: (2022)

Pre-Clinical Models of Diffuse Intrinsic Pontine Glioma
por: Misuraca, Katherine L., et al.
Publicado: (2015)

Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma
por: HASHIZUME, Rintaro
Publicado: (2017)

Hypofractionated radiotherapy in children with diffuse intrinsic pontine glioma
por: Hayashi, Akiko, et al.
Publicado: (2020)

Immune Microenvironment and Immunotherapies for Diffuse Intrinsic Pontine Glioma
por: Chen, Yujia, et al.
Publicado: (2023)

Radiotherapy for Diffuse Intrinsic Pontine Glioma: Insufficient but Indispensable
por: Kim, Hyun Ju, et al.
Publicado: (2023)

Epigenetic and Metabolic Changes in Diffuse Intrinsic Pontine Glioma
por: Park, Jiyoon, et al.
Publicado: (2023)

Attenuated AMPA Receptor Expression Allows Glioblastoma Cell Survival in Glutamate-Rich Environment
por: van Vuurden, Dannis G., et al.
Publicado: (2009)

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
por: Wiele, Andrew J., et al.
Publicado: (2021)

The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis
por: Dai, Jiali, et al.
Publicado: (2019)

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
por: Mesti, Tanja, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_40k4et8d626bb79ctjeih82t3h